Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South America's ALBA group reviews healthcare investment progress and plans:

This article was originally published in Clinica

Executive Summary

The South American and Caribbean region's ALBA group of nations is preparing to launch new public health initiatives in investment-starved areas. Details of the progress and new plans of the Alternativa Bolivariana para las Americas group (comprising Bolivia, Cuba, Nicaragua and Venezuela) were this week presented to the Cuban parliament, by the minister for foreign investment and economic collaboration, Marta Lomas. They feature a commitment to maintain a Cuban-Venezuelan eye surgery project (Operacion Milagro), said to have helped more than 650,000 people regain their sight. Specific plans were not divulged. ALBA focuses on areas in which investment shortfalls have hindered service development in its member countries, such as under the economic and trade blockade imposed by the US on Cuba, but its programmes are said to actively benefit other countries in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel